About us

More about Nanobiotix

Nanobiotix is a nanomedicine company that intends to revolutionize radiotherapy, making it more deadly to tumors while preserving the surrounding healthy tissues.

The company is a spin-off of the State University of New York (SUNY) at Buffalo that has been incorporated in 2003 and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes).

Cancer is now becoming the leading cause of mortality in developing countries. 
Radiotherapy is the most common tool for cancer treatment and is used in 5,000,000 patients every year (representing 60% of total cancer patients).

Despite its widespread usage, however, radiotherapy still exhibits strong limitations due to the irradiation of healthy tissues, which consequently narrows the therapeutic window.
Proprietary Nanobiotix technology - nanoXray™- allows specific and dramatically increased X-ray dosing within a tumor while leaving the surrounding healthy tissue unharmed.

Numerous successful preclinical testing of nanoXray products to treat a variety of cancers has demonstrated the significant potential of this platform and allowed an excellent positioning of nanoXray as a complementary product to standard radiotherapy.

Given its physical mechanism of action, nanoXray is expected to be used in treating several pathologies; for example: glioblastoma multiform, head and neck cancer, lung cancer, and brain metastases.